At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KLRA Kailera Therapeutics
Not Yet Opened 10-19 16:00:00 EDT
11.43
+0.18
+1.60%
盘后11.43
+0.000.00%
19:30 EDT
High11.69Low11.18Vol896.58K
Open11.34D1 Closing11.25Amplitude4.53%
Mkt Cap1.48BTradable Cap513.46MTotal Shares129.54M
T/O10.28MT/O Rate2.00%Tradable Shares44.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Breakingviews-China Biotech's Ingenuity Extends to Dealmaking
Reuters  ·  10-16
Breakingviews-China Biotech's Ingenuity Extends to Dealmaking
U.S. Small Caps Move Upward; Kailera Therapeutics Leads Increases
Dow Jones  ·  10-10
U.S. Small Caps Move Upward; Kailera Therapeutics Leads Increases
Kailera Therapeutics announces positive results from several presentations
TIPRANKS  ·  10-01
Kailera Therapeutics announces positive results from several presentations
Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites
Reuters  ·  10-01
Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
GlobeNewswire  ·  10-01
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)
TIPRANKS  ·  09-30
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)
Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection
Reuters  ·  09-30
Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection
Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028
THOMSON REUTERS  ·  09-30
Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028
Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
THOMSON REUTERS  ·  09-30
Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics to Join Bernstein Insights Healthcare Investor Forum Fireside Chat
Reuters  ·  09-16
Kailera Therapeutics to Join Bernstein Insights Healthcare Investor Forum Fireside Chat
Kailera Therapeutics to Participate in September Investor Conferences
GlobeNewswire  ·  09-16
Kailera Therapeutics to Participate in September Investor Conferences
Kailera Therapeutics CTO Nur Nicholson Files Initial Beneficial Ownership Statement
Reuters  ·  09-10
Kailera Therapeutics CTO Nur Nicholson Files Initial Beneficial Ownership Statement
Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  08-13
Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-13
Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Benzinga Earnings  ·  08-13
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million
Reuters  ·  08-13
Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million
Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027
THOMSON REUTERS  ·  08-13
Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027
Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027
THOMSON REUTERS  ·  08-13
Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
THOMSON REUTERS  ·  08-13
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kailera Therapeutics Names Nur Nicholson Chief Technology Officer
Reuters  ·  08-11
Kailera Therapeutics Names Nur Nicholson Chief Technology Officer

Introduction

Company Name.
Kailera Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Kailera Therapeutics, Inc. was incorporated under the laws of Delaware on May 8, 2024. The company is a clinical-stage biotechnology company dedicated to ushering in a new era of obesity treatment through the advancement of a diversified R&D pipeline. It is currently rapidly advancing four clinical-stage product candidates that leverage multiple glucagon-like peptide-1 (GLP-1)-based mechanisms of action and routes of administration.
Issue price:
--